Arjan Gower, MD, MS

Dr. Gower is a hematologist and medical oncologist within the Division of Hematology/Oncology with a focus in breast and thoracic cancers. His research interests are in predictive biomarkers of response and resistance to novel therapeutics in lung cancer, with an emphasis on antibody drug conjugates. The lack of predictive biomarkers for these exciting agents remain elusive, and biomarker evaluation is going to be the key moving forward.

Li S, Zeng W, Ni X, Liu Q, Li W, Stackpole ML, Yonggang Z, Gower A, Kostyantyn K, Preeti A, Lu DS, Raman SS, Hsu W, Aberle DR, Magyar CE, French SW, Han SB, Garon EB, Agopian VG, Wong WH, Dubinett SM, Zhou XJ. Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring. PNAS (2023) 120: 28.

Velez MA, Glenn BA, Garia-Jimenez M, Cummings AL, Lisberg A, Nañez A, Radwan Y, Lind-Lebuffe JP, Brodrick PM, Li DY, Fernandez-Turizo MJ, Gower A, Lindenbaum M, Hegde M, Brook J, Grogan T, Elashoff D, Teitell MA, Garon EB. Consent document translation expense hinders inclusive clinical trial enrollment. Nature (2023) 620: 855-862.

Gower A and Garon EB. Targeting more precisely: Improving sensitivity to EGFR inhibitors in NSCLC. Med (2021) 2: 1201-1202.

Gower A and Garon EB. Pembrolizumab in Advanced NSCLC: Safety implications of dose adjustments. Translational Clinical Medicine (2022) 11: 4479-4481.